TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $16.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-05-09
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $16.00K, a 1500.00% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $38.00K.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $46.00K.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-06-30 was $38.00K.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $123.00K, a 146.00% increase from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $50.00K, a 97.26% decline from fiscal 2021.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $1.83M, a 12.08% decline from fiscal 2020.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $2.08M, a 40.89% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-03-31 | $16.00K 10-Q · filed 2024-05-09 | $54.00K derived: sum of 2 quarters · filed 2024-05-09 | $100.00K derived: sum of 3 quarters · filed 2024-05-09 | $138.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $84.00K derived: sum of 2 quarters · filed 2024-03-14 | $122.00K derived: sum of 3 quarters · filed 2024-03-14 | $123.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $84.00K derived: sum of 2 quarters · filed 2023-11-09 | $85.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $39.00K 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $50.00K 10-K · filed 2024-03-14 | |||
| 2021-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $97.00K derived: sum of 2 quarters · filed 2023-03-23 | $97.00K derived: sum of 3 quarters · filed 2023-03-23 | $1.83M 10-K · filed 2023-03-23 |
| 2021-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $31.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.76M 10-Q · filed 2022-11-08 | $3.24M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.73M 10-Q · filed 2022-08-09 | $3.21M derived: sum of 3 quarters · filed 2022-08-09 | $3.26M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.73M 10-Q · filed 2022-05-10 | $3.21M derived: sum of 2 quarters · filed 2022-05-10 | $3.26M derived: sum of 3 quarters · filed 2022-05-10 | $3.67M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.53M derived: sum of 2 quarters · filed 2022-03-17 | $1.94M derived: sum of 3 quarters · filed 2022-03-17 | $2.08M 10-K · filed 2022-03-17 |
| 2020-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $462.00K derived: sum of 2 quarters · filed 2021-11-04 | $595.00K 10-Q · filed 2021-11-04 | $663.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $413.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $546.00K 10-Q · filed 2021-08-05 | $614.00K derived: sum of 3 quarters · filed 2021-08-05 | $711.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $133.00K 10-Q · filed 2021-05-13 | $201.00K derived: sum of 2 quarters · filed 2021-05-13 | $298.00K derived: sum of 3 quarters · filed 2021-05-13 | $2.28M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $165.00K derived: sum of 2 quarters · filed 2021-03-18 | $2.15M derived: sum of 3 quarters · filed 2021-03-18 | $3.51M 10-K · filed 2021-03-18 |
| 2019-09-30 | $97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.08M derived: sum of 2 quarters · filed 2020-11-05 | $3.45M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $3.35M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $1.36M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $410.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |